KPTI — Karyopharm Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1503802 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
2026-11-20
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 33,432,000 | 32,347,000 | -22,526,000 | -67,023,000 | 111,317,000 | 54,980,000 | 441,485,000 |
| Mar 2026 | 35,066,000 | 33,721,000 | -26,760,000 | -22,392,000 | 131,417,000 | 90,850,000 | 397,063,000 |
| Dec 2025 | 34,079,000 | 32,595,000 | -17,844,000 | -102,198,000 | 108,416,000 | 60,540,000 | 401,342,000 |
| Sep 2025 | 44,044,000 | 41,931,000 | -15,220,000 | -33,127,000 | 96,232,000 | 37,672,000 | 365,490,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-65,347,000
Investing CF
$2,969,000
Financing CF
$78,596,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-13.09
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,848,914,000
Inventory
$3,994,000
Receivables
$29,871,000
ST Investments
$10,125,000
EBIT TTM
$-175,448,000
Pretax Income TTM
$-224,772,000
Interest Exp TTM
$49,324,000
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$146,620,992
EBITDA
$-82,201,000
Free Cash Flow
$-29,674,250
Enterprise Value
$299,942,144
Total Cash
$65,105,000
Total Debt
$328,529,984
Shares Out
22,681,460
Trailing EPS
$-14.33
Book Value
$-14.56
ROE
—
ROA
-47.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 146,067,000 | -90,707,000 | -196,039,000 | 108,416,000 | 401,342,000 | -292,926,000 | -75,369,000 |
| Dec 2024 | 145,237,000 | -119,443,000 | -76,422,000 | 164,418,000 | 350,435,000 | -186,017,000 | -127,486,000 |
| Dec 2023 | 146,033,000 | -129,540,000 | -143,099,000 | 240,438,000 | 376,644,000 | -136,206,000 | -92,723,000 |
| Dec 2022 | 157,074,000 | -142,202,000 | -165,291,000 | 358,172,000 | 374,828,000 | -16,656,000 | -149,554,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$146,621,000
NetIncome TTM
$-224,740,000
OpCashFlow TTM
—
Assets (Latest)
$111,317,000
Forward EPS
$-2.82
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.26T | $1415.55 | — |
| JNJ | JOHNSON & JOHNSON | $670.92B | $278.70 | — |
| ABBV | AbbVie Inc. | $517.59B | $292.82 | — |
| MRK | Merck & Co., Inc. | $353.44B | $143.37 | — |
| NVS | NOVARTIS AG | $302.46B | $159.13 | — |
News headlines (Yahoo Finance, 1h cache)
Karyopharm to Present Selinexor Data in Patients with Myelofibrosis and Multiple Myeloma at the 68th American Society of Hematology Annual Meeting and Exposition (ASH)
2026-11-04 14:01 · Yahoo
Karyopharm, deep in debt, to sell itself in bankruptcy
2026-11-02 17:07 · Yahoo
Karyopharm Therapeutics Files for Chapter 11 Bankruptcy and Agrees to Planned Merger with Ayrmid
2026-11-02 15:52 · Yahoo
Karyopharm Therapeutics Inc. Announces Planned Merger with Ayrmid Ltd. to Strengthen Company for the Future
2026-11-02 12:10 · Yahoo
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-10-01 20:05 · Yahoo
Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use
2026-09-11 09:37 · Yahoo
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-01 20:05 · Yahoo
Karyopharm (KPTI) Q2 2026 Earnings Call Transcript
2026-08-20 13:43 · Yahoo
Karyopharm Therapeutics Inc (KPTI) (Q2 2026) Earnings Call Highlights: SENTRY Trial Success and ...
2026-08-13 23:09 · Yahoo
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Beats Revenue Estimates
2026-08-13 12:50 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.